Context

Bone Therapeutics is a bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases.

They announced positive interim results for its ALLOB Phase I/IIA delayed-union study and its ALLOB Phase IIA spinal fusion study.

The fundraising was required to finance ongoing R&D programs.

Interim results for the PREOB Osteonecrosis study and launch of ALLOB Ph IIB are expected in 2018 H2.

About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Their technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells.

The company’s primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, additionally they also have an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip.

Discover Bone Therapeutics

Hervé Ronin

Investment Banking

Jean de Pracomtal

Investment Banking

Dr. Anne Moore

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center